Posted by Michael Wonder on 07 Jan 2025
Norgine submits marketing authorisation application to the EMA for eflornithine (difluoromethylornithine) in high risk neuroblastoma
6 January 2025 - Norgine today announced that it completed its marketing authorisation application filing to the EMA for eflornithine in high-risk neuroblastoma.
This follows the submissions in April 2024, via Project Orbis, in Australia, Switzerland and the United Kingdom.
